(
Back to our regularly scheduled program . . . though I will continue to post highlights from Blogging for LGBT Families Day for a while.)
Scientists have shown that a new experimental drug, Tykerb, slows the growth of breast cancer even when existing “new generation” drugs like Herceptin fail to work. A controlled study of Tykerb was so successful that it was stopped in order to give all participants the drug. Tykerb, given as a pill, is also easier to take than intravenous Herceptin. One doctor not associated with the study calls the news of Tykerb “huge.”
Some further study is needed, but Tykerb’s maker, GlaxoSmithKline, will seek approval to sell it in the U. S. and elsewhere later this year.